Nitin Roper

Abstract B005: ADT-030, a novel PDE10 inhibitor that blocks RAS and β-catenin signaling with robust and durable antitumor activity and potential to mitigate resistance and on-target toxicities of monospecific RAS inhibitors

Multiple cancers arise from co-occurring mutations that activate RAS/MAPK and Wnt/β-catenin signaling pathways, which cooperate to drive tumorigenesis, metastasis, and drug resistance. A dual inhibitor of RAS and β-catenin signaling may offer a more effective therapeutic strategy compared with monospecific inhibitors...